Mason Street Advisors LLC Buys 350 Shares of Cardiovascular Systems Inc (NASDAQ:CSII)

Mason Street Advisors LLC increased its stake in Cardiovascular Systems Inc (NASDAQ:CSII) by 3.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,975 shares of the medical device company’s stock after purchasing an additional 350 shares during the period. Mason Street Advisors LLC’s holdings in Cardiovascular Systems were worth $569,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of Cardiovascular Systems by 1.1% in the second quarter. BlackRock Inc. now owns 5,508,322 shares of the medical device company’s stock worth $236,471,000 after purchasing an additional 59,146 shares during the period. Brown Capital Management LLC increased its position in shares of Cardiovascular Systems by 21.7% in the second quarter. Brown Capital Management LLC now owns 4,563,352 shares of the medical device company’s stock worth $195,905,000 after purchasing an additional 812,595 shares during the period. Vanguard Group Inc. increased its position in shares of Cardiovascular Systems by 2.3% in the second quarter. Vanguard Group Inc. now owns 2,194,713 shares of the medical device company’s stock worth $94,218,000 after purchasing an additional 49,401 shares during the period. Renaissance Technologies LLC increased its position in shares of Cardiovascular Systems by 4.0% in the second quarter. Renaissance Technologies LLC now owns 1,180,100 shares of the medical device company’s stock worth $50,662,000 after purchasing an additional 45,200 shares during the period. Finally, Northern Trust Corp increased its position in shares of Cardiovascular Systems by 1.8% in the second quarter. Northern Trust Corp now owns 471,730 shares of the medical device company’s stock worth $20,252,000 after purchasing an additional 8,517 shares during the period. Institutional investors own 89.53% of the company’s stock.

In other Cardiovascular Systems news, General Counsel Alexander Rosenstein sold 6,308 shares of Cardiovascular Systems stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $50.42, for a total value of $318,049.36. Following the transaction, the general counsel now owns 78,187 shares in the company, valued at $3,942,188.54. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.

A number of research firms have issued reports on CSII. BidaskClub cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Needham & Company LLC reiterated a “hold” rating on shares of Cardiovascular Systems in a research report on Wednesday, August 7th. Guggenheim began coverage on Cardiovascular Systems in a research report on Thursday, October 17th. They issued a “buy” rating and a $58.00 target price on the stock. ValuEngine cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Lake Street Capital lifted their target price on Cardiovascular Systems from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Cardiovascular Systems has an average rating of “Hold” and an average price target of $50.20.

Cardiovascular Systems stock opened at $44.29 on Thursday. Cardiovascular Systems Inc has a 12-month low of $24.84 and a 12-month high of $52.54. The company has a quick ratio of 3.04, a current ratio of 3.45 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $45.77 and its two-hundred day moving average price is $44.66. The stock has a market cap of $1.56 billion, a PE ratio of -4,429.00 and a beta of 1.62.

Cardiovascular Systems (NASDAQ:CSII) last released its earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.09). Cardiovascular Systems had a negative net margin of 1.23% and a negative return on equity of 2.21%. The business had revenue of $64.49 million during the quarter, compared to the consensus estimate of $64.03 million. As a group, analysts expect that Cardiovascular Systems Inc will post -0.06 earnings per share for the current year.

Cardiovascular Systems Profile

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Featured Article: What is a Call Option?

Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems Inc (NASDAQ:CSII).

Institutional Ownership by Quarter for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.